←
Illumina Ventures958 posts
Illumina Ventures avatar

Illumina Ventures

@illuminaventure

Independent, exclusively genomics- and precision medicine-focused firm investing in pioneering tools, therapeutics and diagnostics.

◷ Joined March 2016▧ 332 Photos and videos
Illumina Ventures avatar
Illumina Ventures@illuminaventure·Jan 16

At #RESIJPM 2026, Founding Partner Nick Naclerio, PhD, moderated the Techbio & Synthetic Biology panel. With Chris Yoo, Rohit Jain, Cristina Escoda and Yaron Daniely, he explored why now is a pivotal moment for the sector and what's needed in the capital-conscious market. #RESI

Post attachment
Illumina Ventures avatar
Illumina Ventures@illuminaventure·Jan 13

Encouraging news from portfolio company @EncodedTx: the FDA granted Breakthrough Therapy Designation to investigational ETX101 for Dravet syndrome—an important step that can help accelerate development in close collaboration with the FDA. encoded.com/press-releases/e… #PartnerNews

Exciting news: The FDA granted Breakthrough Therapy Designation to ETX101 based on clinical evidence from the POLARIS Phase 1/2 trials. This designation is reserved for therapies that show early signs of meaningful improvement and is intended to accelerate development and regulatory review. This marks an important milestone in advancing ETX101 with urgency and care for patients and families living with Dravet syndrome. Read today’s release for more information: ow.ly/qQNH50XVKtb #DravetSyndrome

Post attachment
Illumina Ventures avatar
Illumina Ventures@illuminaventure·Jan 12

Portfolio company @Precede_Bio secured $83.5M to scale its blood-based epigenomic platform for next-gen precision medicines. Founding Team Member & Partner Wouter Meuleman, PhD, also joined Precede’s Board. Details: precede.bio/news/seriesb-fin… #LiquidBiopsy #PartnerNews

We’re proud to share that Precede Biosciences has secured $83.5M in total financing to scale our next-generation precision diagnostics platform. This capital supports continued growth amid strong commercial traction with leading biopharmaceutical developers advancing the next wave of precision medicines. More broadly, this milestone reflects growing conviction in the need for diagnostics built for target expression and pathway biology, the biomarkers most relevant to next-generation precision medicines, including antibody drug conjugates (ADCs), targeted protein degraders, and other next-generation precision medicines. We’re grateful for the continued support of our existing investors, including Illumina Ventures, 5AM Ventures, Bristol Myers Squibb, Osage University Partners (OUP), Binney Street Capital, and Lilly Asia Ventures, and excited to welcome new strategic and institutional partners, including Labcorp Venture Fund, UPMC Enterprises, Mirae Asset Capital Life Science, Mirae Asset Capital, 28 Capital LLC, and Alexandria Venture Investments. We’re also grateful for the commitment and belief of the team at SVB, who support the Precede Bio mission through strategic, non-dilutive financing. Together, this group adds deep expertise to the Precede mission, a mission to meaningfully impact drug development success rates and ensure patients receive treatments fully aligned to the biology of their disease. View press release: precede.bio/news/seriesb-fin…

Post attachment
Illumina Ventures avatar
Illumina Ventures@illuminaventure·14 Nov 2025

Founding Partner Nick Naclerio, PhD, will join LinkBridge Investors’ Global Investors Annual Meeting on 11/18 in Newport Beach, CA with leading VCs and investors for panels and 1:1 discussions on emerging market trends and strategies. Details: linkbridgeinvestors.com/

Post attachment